Sector
PharmaceuticalsOpen
₹21.7Prev. Close
₹21.97Turnover(Lac.)
₹7.26Day's High
₹22.27Day's Low
₹21.3252 Week's High
₹31.252 Week's Low
₹14.3Book Value
₹-122.33Face Value
₹2Mkt Cap (₹ Cr.)
116.13P/E
2.98EPS
7.4Divi. Yield
019 Aug 2024
12:00 AM
BookCloser
1 Aug 2024
12:00 AM
Board Meeting
Agenda : Audited Result
2 Sep 2024
12:00 AM
AGM
Announcement Date: 02 Sep, 2024
6 Sep 2023
12:00 AM
EGM
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 10.83 | 10.83 | 10.83 | 10.83 |
Preference Capital | 14.2 | 14.2 | 14.2 | 14.2 |
Reserves | -701.66 | -715.53 | -731.15 | -706 |
Net Worth | -676.63 | -690.5 | -706.12 | -680.97 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 356.05 | 329.52 | 269.81 | 263.05 |
yoy growth (%) | 8.05 | 22.12 | 2.56 | -14.52 |
Raw materials | -186.52 | -186.89 | -154.15 | -166.02 |
As % of sales | 52.38 | 56.71 | 57.13 | 63.11 |
Employee costs | -55.79 | -52.52 | -48.26 | -42.38 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -28.28 | -23.06 | -25.22 | -103.76 |
Depreciation | -32.7 | -33.59 | -34.63 | -35.73 |
Tax paid | -0.32 | -2.46 | -0.75 | -0.89 |
Working capital | -9.72 | -14.89 | -20.1 | -383.71 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 8.05 | 22.12 | 2.56 | -14.52 |
Op profit growth | 77.3 | 270.66 | -109.62 | -58.33 |
EBIT growth | 219.15 | -130.93 | -79.22 | -51.62 |
Net profit growth | 55.93 | -64.67 | -85.14 | 82.18 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|---|
Gross Sales | 502.25 | 410.96 | 397.71 | 270.57 | 267.2 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 502.25 | 410.96 | 397.71 | 270.57 | 267.2 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 57.99 | 72.43 | 24.28 | 10.16 | 13.68 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,897 | 163.49 | 4,55,021.88 | 237.82 | 0.71 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,925 | 94.67 | 1,57,256.95 | 430 | 0.51 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,523.75 | 30.97 | 1,22,988.41 | 1,055.94 | 0.85 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,392.5 | 76.4 | 1,14,822.61 | 469 | 0.83 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,697.4 | 27.12 | 1,11,742.47 | 1,417.2 | 0.6 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director & CEO
G Munjal
Chairman & Exec. Director
S R Mehta
Joint Managing Director
V R Mehta
Non-Exec & Non-Independent Dir
Himanshu Jain
Non-Exec & Non-Independent Dir
N R Munjal
Non-Exec & Non-Independent Dir
Rishav Mehta
Non-Exec. & Independent Dir.
S P Sharma
Non-Exec. & Independent Dir.
V K Arora
Non-Exec. & Independent Dir.
Subhash Chander Galhotra
Non-Exec. & Independent Dir.
Anoop Michra
Non-Exec. & Independent Dir.
Jagvir Singh Ahluwalia
Company Sec. & Compli. Officer
Ginny Uppal
Independent Director
Bhupinder Singh
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ind-Swift Ltd
Summary
Ind-Swift Ltd (ISL) is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of pharmaceutical finished dosage. The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables. The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.Ind-Swift Ltd was incorporated in the year 1986. In the year 1991, the company set up a manufacturing facility for injectables and eye/ear drops. In the year 1995, they incorporated Ind-Swift Laboratories Ltd for initiating a backward integration into the manufacturing of APIs and advanced intermediates.In the year 1997, the company commissioned a multipurpose plant with five independent blocks erected as per US FDA standards, designed by Quara, Switzerland. In addition, they launched a Marketing Division with the name Ind-Swift Health Care.In the year 2000, the company launched Super Specialty
Read More
What is the Ind-Swift Ltd share price today?
The Ind-Swift Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹21.44 today.
What is the Market Cap of Ind-Swift Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ind-Swift Ltd is ₹116.13 Cr. as of 21 Oct ‘24
What is the PE and PB ratio of Ind-Swift Ltd?
The PE and PB ratios of Ind-Swift Ltd is 2.98 and -0.17 as of 21 Oct ‘24
What is the 52 Week High and Low of Ind-Swift Ltd?
The 52-week high/low is the highest and lowest price at which a Ind-Swift Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ind-Swift Ltd is ₹14.3 and ₹31.2 as of 21 Oct ‘24
What is the CAGR of Ind-Swift Ltd?
Ind-Swift Ltd's CAGR for 5 Years at 37.90%, 3 Years at 16.24%, 1 Year at 40.59%, 6 Month at 5.36%, 3 Month at 5.10% and 1 Month at -9.80%.
What is the shareholding pattern of Ind-Swift Ltd?
The shareholding pattern of Ind-Swift Ltd is as follows:
Promoters - 55.58 %
Institutions - 0.00 %
Public - 44.42 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
